Vincent Stephenne, managing director of Belgian CDMO BePharBel Manufacturing, highlights the company’s innovative approach to developing new galenic forms for existing molecules, its growth trajectory thus far, and his future plans for partnership strategies and expansion.
Recently we have patented the new MMCR technology (for multi-layer microparticle controlled-release system) enabling us to convert a well-established API from tablets to syrup, with the benefit of facilitating intake for elderly people and children and with the possibility to have a controlled release (delayed or sustained)
